Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCL mRNA LNP
- Development stage
- Unknown
- Lead developer
- Formula 1
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SCL (Synthetic CAR Ligand) mRNA LNP is an off-the-shelf messenger RNA therapy formulated in lipid nanoparticles, developed by Exuma Biotechnology. It is designed to provide in vivo control over the expansion and persistence of CAR-T cells, a process the company describes as "CAR-T recharge." The mRNA encodes a synthetic ligand (a non-CAR target epitope construct) that, upon expression in the patient, interacts with the chimeric antigen receptor (CAR) on T-cells to provide a stimulus for their activity. This technology is intended to enhance the therapeutic efficacy and durability of CAR-T cell therapies for both solid tumors and hematological malignancies. It is currently being evaluated in Phase 1/2 clinical trials, notably in combination with Exuma's GCAR™ platform for the treatment of Large B-Cell Lymphoma.
- Other names
- Synthetic CAR Ligand mRNA lipid nanoparticle
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on SCL mRNA LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCL mRNA LNP.